Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-arginine-enriched blood cardioplegia in coronary artery bypass surgery for severe ischemic cardiomyopathy
ACTRN12610000203055Phase 3Completed
- Sponsor
- David Andrews
- Start
- Sep 2005
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of arginine in ischaemic cardiomyopathy (ICM) and coronary arteriosclerosis (2 arms), sponsored by David Andrews. Primary endpoint: Whole blood cardiac troponin I concentration. Started Sep 2005; status: completed.
02
Drugs
arginine
03
Conditions
ischaemic cardiomyopathy (ICM)coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12610000203055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000203055.